可切除非小细胞肺癌新辅助免疫治疗的最新应用进展  

Recent progress of neoadjuvant immunotherapy for resectable non-small cell lung cancer

作　　者：张梦颖 孙树印[2] 马会平[2] Zhang Mengying;Sun Shuyin;Ma Huiping(Shandong First Medical University Graduate School of Shandong Academy of Medical Sciences,Jinan 250000,China;Department of Respiratory and Critical Care Medicine,Jining First People's Hospital,Jining 272000,China)

机构地区：[1]山东第一医科大学山东省医学科学院研究生部,济南250000 [2]济宁市第一人民医院呼吸与危重症医学科,济宁272000

出　　处：《国际呼吸杂志》2022年第19期1503-1509,共7页International Journal of Respiration

摘　　要：肺癌是全球癌症相关死亡的主要原因。非小细胞肺癌(NSCLC)占每年新发肺癌的80%~85%, 可切除的NSCLC患者通常采用手术和新辅助/辅助化疗治疗, 然而由于化疗不良反应明显, 患者耐受性差, 相较于单纯手术, 无论是新辅助还是辅助化疗仅能提高这些患者5%左右的5年生存率。如何优化治疗策略, 延长患者的生存期, 是目前国内外肺癌研究的热点。与传统化疗相比, 免疫治疗有更好的耐受性, 同时与治疗相关的毒性对手术切除的影响较小。近年来, 免疫治疗迅速从晚期NSCLC前移到疾病更早期, 从姑息性治疗向新辅助及辅助治疗领域探索。多项研究已表明新辅助免疫治疗可以提高患者生存率。但是其受益人群的选择、治疗方案的制定以及不良事件的管理等都是目前亟需解决的问题。Lung cancer is the leading cause of cancer-related deaths in the world.Non-small cell lung cancer(NSCLC)accounts for 80%~85% of new lung cancer yearly.Resectable NSCLC patients are normally treated with surgeries or neoadjuvant/adjuvant chemotherapies.While chemotherapy is noted to have evident adverse reaction and poor tolerance of patients,both neoadjuvant and adjuvant chemotherapy can only improve the five-year survival rate of the patients by approximately 5%compared with surgery alone.It is the trending of domestic and overseas studies on lung cancer currently for how to optimize the treatment strategy and prolong the survival time of patients.Immunotherapy demonstrates better tolerance compared with traditional chemotherapy,and the treatment-related toxicity has less impacts on surgical resection.Immunotherapy has rapidly moved from advanced NSCLC to earlier period of the disease in recent years,and explored from palliative therapy to neoadjuvant and adjuvant therapy.The studies have proven that neoadjuvant immunotherapy supported improving the survival rate of patients.Whereas,the selection on benefiting group,formulation of treatment plans and management of adverse events are problems to be imperatively solved.

关 键 词：癌 非小细胞肺 新辅助治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]